AstraZeneca

Study proves effectiveness of Pulmicort

Published in Medical Device Law Weekly, February 27th, 2005

New results from the START study have been published in the Annals of Allergy, Asthma and Immunology, revealing 3-year safety outcome data for Pulmicort (budesonide).

These data further reinforce previous findings that Pulmicort in low doses is well tolerated in long term treatment of asthma in both adults and children.

Patients enlisted in the START study, the largest ever controlled asthma trial involving more than 7,000 patients in 32 different countries, were aged from 5-66 years and randomized to receive either Pulmicort or placebo once daily in addition to their usual asthma therapy.

Pulmicort was taken viaTurbuhaler...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Device Law Weekly

Source: Medical Device Law Weekly (2005-02-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry